Released Mar 30, 2023, after the close
10-K filed Mar 30, 2023, 89 days after period end · 0000950170-23-010921
Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$278.00K$278.00K derivedno prior Q4 2021 on file−74.3% vs Q3 2022
Net Income$26.79M$26.79M derivedN/M vs Q4 2021N/M vs Q3 2022
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived$25,924,000N/M
Operating Cash Flowderived$44,482,000N/M
Margins · derived
Operating margin9325.2%
Net margin9634.9%
What the release said
The release
Same quarter
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019 |
|---|---|---|---|---|
| Revenue | $278.00K | — | $0.00 | $696.00K |
| Net Income | $26.79M | -$29.30M | -$18.60M | -$24.99M |
| EPS Diluted | — | — | — | -$1.31 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR